AUROPHARMABSEAurobindo Pharma LtdMediumNeutral
Announced Sat, 16 May · 21:40 IST

intimation of receipt of Order form the Hon''ble High Court of Telangana, Hyderabad by the promoters of the Company.

Insider Trading ChargeLitigation LossSebi PenaltyRegulatory & Legal View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.2%1-day move
₹1510.30
prior close
₹1514.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.3-0.0-0.5+0.2+0.7+2.6-2.8-3.7-5.2-4.7-4.3+3.2
Up moveDown movePending
AI summary

Aurobindo Pharma's promoters received an adverse court order regarding a SEBI insider trading settlement case. The promoters—Mr. P.V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited—had filed a writ petition to challenge SEBI's October 2020 directive to deposit Rs. 6.53 crores in profits (plus 12% interest) into the Investor Protection and Education Fund. This was in connection with alleged violations of insider trading regulations under SEBI PIT Regulations, 1992. The Hon'ble High Court of Telangana dismissed the writ petition on May 6, 2026. The promoters will decide on further legal action in consultation with their legal advisors. The company clarified that since the order is against the petitioners (promoters), there is no impact on Aurobindo Pharma's financials or operations.

Likely market impact

The company itself faces no financial or operational impact as the order is directed at the promoters. However, this creates reputational concerns around promoter-level insider trading allegations and ongoing regulatory scrutiny that may worry some investors.